« Back
Home /
PF-562271

PF-562271

Item no.	HY-10459-25mg
Manufacturer	MedChem Express
CASRN	717907-75-0
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	99.68
Citations	[1]Roberts WG, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res, 2008, 68(6), 1935-1944.\|[2]Crompton BD, et al. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res. 2013 May 1;73(9):2873-83.\|[3]Bagi CM, et al. Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases. Cancer. 2008 May 15;112(10):2313-21. Anticancer Drugs. 2023 Jul 14.\|Breast Cancer Res. 2024 Mar 19;26(1):48.\|Cancer Res. 2013 May 1;73(9):2873-83.\|Carbohydr Polym. 2024 Feb 15, 326, 121637.\|Cell Death Dis. 2022 Sep 10;13(9):783.\|Cell Death Dis. 2023 Feb 24;14(2):157.\|Cell Discov. 2022 Sep 6;8(1):84.\|Cell Rep. 2023 Oct 5;42(10):113213.\|Clin Cancer Res. 2019 Jul 15;25(14):4552-4566.\|Environ Toxicol Pharmacol. 2023 Oct 20:104301.\|Eur J Cell Biol. 2024 May 28;103(2):151427.\|Harvard Medical School LINCS LIBRARY\|Int J Cancer. 2015 Oct 1;137(7):1549-59.\|J Nat Med. 2020 Sep;74(4):732-740.\|Life Sci. 2021 Jan 25;119112.\|Practical Oncology Journal. 2015, 29(5): 444-449.\|Research Square Preprint. 2021 Dec.\|Research Square Preprint. 2023 May 23.\|Sci Rep. 2018 May 8;8(1):7228. \|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
Smiles	CS(=O)(N(C)C1=NC=CC=C1CNC2=NC(NC3=CC4=C(C=C3)NC(C4)=O)=NC=C2C(F)(F)F)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	VS-6062
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	FAK; Pyk2
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	507.49
Product Description	PF-562271 (VS-6062) is a potent, ATP-competitive and reversible FAK and Pyk2 kinase inhibitor with IC50s of 1.5 nM and 13 nM, respectively[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 66.67 mg/mL (ultrasonic)
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Clinical information	Phase 1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10459-25mg-safety-datasheet.pdf